Hello, Fool! | Login | Signup | My Fool
Oct 12, 2008 2:34 PM ET | Feedback | Site Changes | Help
The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.
View All Commentary (HGSI)
Recs
FaithInValue (85.58) Submitted: 6/30/08 3:35 PM : Start Price: $5.25 HGSI Score: 1.84
couple good products coming out in the future, expected to pick up slack from where compeititors failed (lupus drug). Also, have the ability to specifically supply the gov.
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK